Mycosis fungoides and Sézary syndrome: focus on the current treatment scenario
An. bras. dermatol
;
96(4): 458-471, July-Aug. 2021. tab
Article
in English
| LILACS
| ID: biblio-1285098
ABSTRACT
Abstract Cutaneous T-cell lymphomas are a heterogeneous group of lymphoproliferative disorders, characterized by infiltration of the skin by mature malignant T cells. Mycosis fungoides is the most common form of cutaneous T-cell lymphoma, accounting for more than 60% of cases. Mycosis fungoides in the early-stage is generally an indolent disease, progressing slowly from some patches or plaques to more widespread skin involvement. However, 20% to 25% of patients progress to advanced stages, with the development of skin tumors, extracutaneous spread and poor prognosis. Treatment modalities can be divided into two groups skin-directed therapies and systemic therapies. Therapies targeting the skin include topical agents, phototherapy and radiotherapy. Systemic therapies include biological response modifiers, immunotherapies and chemotherapeutic agents. For early-stage mycosis fungoides, skin-directed therapies are preferred, to control the disease, improve symptoms and quality of life. When refractory or in advanced-stage disease, systemic treatment is necessary. In this article, the authors present a compilation of current treatment options for mycosis fungoides and Sézary syndrome.
Full text:
Available
Index:
LILACS (Americas)
Main subject:
Skin Neoplasms
/
Lymphoma, T-Cell, Cutaneous
/
Mycosis Fungoides
/
Sezary Syndrome
Limits:
Humans
Language:
English
Journal:
An. bras. dermatol
Journal subject:
Dermatology
Year:
2021
Type:
Article
Affiliation country:
Brazil
Institution/Affiliation country:
Private Institution/BR
/
Universidade de São Paulo/BR
Similar
MEDLINE
...
LILACS
LIS